Search
Worldwide Contacts Animal Health Partnering May 2024
Animal Health Partnering Guide.pdf
Animal Health Partnering Outlook
Partnering with Animal Health MAY 2024 CORP_0.pdf
BI_Animal_Welfare_Backgrounder.pdf
BI_Animal_Health.pdf
Human-animal_bond_survey.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
Boehringer Ingelheim Animal Health Business Unit Factsheet_2.pdf
The Research Process
The Research Process
Genomic Lens Linking Worlds in DNA
Adding a new dimension to drug discovery with the help of data science and DNA
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Our partners university of georgia
We're partnering with the University of Georgia to address unmet needs and find solutions to some of the biggest challenges in animal health.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.